Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Lung and Other Respiratory" returned 5 results:

Effects of a dietary supplement (SV) on advanced non small cell lung cancer patients treated with best supportive care (BSC): A randomized double-blind placebo controlled study, a phase III Trial
Principal Investigator(s): Henry Sacks

A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Phase 2 Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo for Tumor Control in Patients with well Differentiated, Advanced Lung or Thymus Neuroendocrine Tumors (SPINET)
Principal Investigator(s): Michelle Kim

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) (Protocol# D4191C00001)
Principal Investigator(s): Dr. Jorge Gomez

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator(s): Dr. Jorge Gomez

A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)
Principal Investigator(s): Dr. Jorge Gomez